Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fetal hemoglobin (HbF, α2γ2) induction is a therapeutic strategy that aims to increase the production of HbF in adults, particularly in patients with β-hemoglobinopathies like sickle cell disease and β-thalassemia. This is achieved through various mechanisms including epigenetic modification of γ-globin genes and modulation of transcription factors that regulate their expression.
Reactivation/upregulation of HBG1/HBG2 genes encoding gamma globins through epigenetic modification (DNA/histone) or transcription factor modulation.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fetal Hemoglobin Induction (HbF Induction).